247 related articles for article (PubMed ID: 17276779)
1. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.
Sinha A; Levine O; Knoll MD; Muhib F; Lieu TA
Lancet; 2007 Feb; 369(9559):389-96. PubMed ID: 17276779
[TBL] [Abstract][Full Text] [Related]
2. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis.
Sinha A; Constenla D; Valencia JE; O'Loughlin R; Gomez E; de la Hoz F; Valenzuela MT; de Quadros CA
Rev Panam Salud Publica; 2008 Nov; 24(5):304-13. PubMed ID: 19141172
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
8. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
9. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
Lieu TA; Ray GT; Black SB; Butler JC; Klein JO; Breiman RF; Miller MA; Shinefield HR
JAMA; 2000 Mar; 283(11):1460-8. PubMed ID: 10732936
[TBL] [Abstract][Full Text] [Related]
10. Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia.
Gargano LM; Hajjeh R; Cookson ST
Prehosp Disaster Med; 2015 Aug; 30(4):402-11. PubMed ID: 26061190
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay.
Constenla DO
Rev Panam Salud Publica; 2008 Aug; 24(2):101-12. PubMed ID: 19062601
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Giglio N; Gentile A; Jimenez SG; Jáuregui B; Clark AD; Diosque M; Vizzotti C
Vaccine; 2011 Jul; 29(31):4963-72. PubMed ID: 21621575
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
Giglio ND; Cane AD; Micone P; Gentile A
Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
[TBL] [Abstract][Full Text] [Related]
14. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
Giorgi-Rossi P; Merito M; Borgia P
Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
17. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
19. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
20. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
